Nominations open for the 2026 ASCI / Stanley J. Korsmeyer Award

Nominations for the ASCI’s 2026 ASCI / Stanley J. Korsmeyer Award are now open.

This prestigious recognition, first called the ASCI Award, was renamed in 2006 in honor of Dr. Korsmeyer, the first recipient of the Award in 1998, who passed away in 2005. The Award recognizes individuals for their advancement of knowledge in a specific field and for mentoring future generations of life science researchers. Information on all past honorees is available here.

The Awardee delivers the Korsmeyer Award Lecture at the 2026 AAP/ASCI/APSA Joint Meeting, April 17-19, and receives an unrestricted $20,000 honorarium.

Current Active and International ASCI members are eligible for nomination. Prior nominees who remain eligible may be re-nominated. However, current ASCI Council members and prior Award recipients may not be nominated.

The deadline for receipt of nominations is October 15, 2025, at 11:59 pm Eastern. Nominations will be screened to ensure they are complete and fit the nomination criteria. The Council reviews nominations, with the outcome of review expected toward the end of November 2025.

Nominators:

  • may be any ASCI member in good standing, including members of the Council;
  • must provide a statement (250-word limit) regarding the nominee; and
  • must comment regarding other investigators who have significantly contributed to the discoveries related to the nomination.

Nominees:

  • must currently be an Active or International member (age 55 or younger);
  • must provide a biosketch, full curriculum vitae, and a trainee table;
  • must identify a former mentee to provide a statement of support (500-word limit);
  • must complete the ASCI’s demographic survey; and
  • must identify their research domain(s).

To start a nomination:

Nominations may be started by the nominator or the nominee:

  • Access your member account
  • Go to the “Activities / nominations” tab
  • Go to the section for “ASCI / Stanley J. Korsmeyer Award”

For the nominator:

  • Select “I’m the nominator” option
  • Search for your nominee
  • Click on “Start nomination”
  • If the nominee has not already claimed her/his part of the nomination, click on “Send nominee information to access the nominee’s part of the nomination” to send the nominee an email to access and edit her/his aspect of the nomination (see above).
  • Supply the required information (see above)
  • Submit this aspect of the nomination

For the nominee:

  • Select “I’m the nominee” option
  • Supply the required information (see above)
  • Submit this aspect of the nomination

Nominations open for the 2026 ASCI / Scharschmidt~Crawford Distinguished Lectureship and Award

Nominations for the ASCI’s 2026 Bruce F. Scharschmidt & Peggy S. Crawford Translational Medicine Distinguished Lectureship and Award are now open.

The Award recognizes those who have made important contributions to the development of high-impact diagnostics or therapeutics for patients. The Awardee delivers the Scharschmidt~Crawford Distinguished Lectureship at the annual AAP/ASCI/APSA Joint Meeting and receives an unrestricted $20,000 honorarium. Drs. Scharschmidt and Crawford have pledged a very generous philanthropic gift to the ASCI to fully endow the Award.

Any person with an MD or equivalent, regardless of ASCI membership, is eligible for nomination. However, current ASCI Council members may not be nominated.

The deadline for receipt of nominations is October 15, 2025, at 11:59 pm Eastern. Nominations will be screened to ensure they are complete and fit the nomination criteria. The Council reviews nominations, with the outcome of review expected in December 2025.

Nominators:

  • may be any ASCI member in good standing, including members of the Council, and
  • must provide a statement (250-word limit) regarding the nominee.

Nominees:

  • may be any person with an MD or equivalent, regardless of ASCI membership, but excluding members of the Council;
  • must be able to attend the 2026 Joint Meeting, April 17-19, in Chicago;
  • must provide a 500-word-limit description of their contributions to the development of high-impact diagnostics or therapeutics for patients;
  • must provide a full curriculum vitae;
  • must complete the ASCI’s demographic survey; and
  • must provide information regarding their research domain(s).

To start a nomination:

Nominations may be started by the nominator or the nominee:

  • Access your member account
  • Go to the “Activities / nominations” tab
  • Go to the section for “ASCI / Scharschmidt~Crawford Distinguished Lectureship and Award”

For the nominator:

  • Select “I’m the nominator” option
  • Search for your nominee
  • Click on “Start nomination”
  • If the nominee has not already claimed her/his part of the nomination, click on “Send nominee information to access the nominee’s part of the nomination” to send the nominee an email to access and edit her/his aspect of the nomination (see above).
  • Supply the required information (see above)
  • Submit this aspect of the nomination

For the nominee:

… if the nominee is an ASCI member:

  • Select “I’m the nominee” option
  • Supply the required information (see above)
  • Submit this aspect of the nomination

… if the nominee is not ASCI member, the nominee can email staff@the-asci.org to have a nomination set up by staff.

Nominations for Active and International membership, 2026

Nominations for Active and International membership for 2026 are open and may be submitted through the deadline of September 10, 2025, 11:59 pm Eastern. All participants in a nomination should carefully review the information below. Send questions to staff@the-asci.org.

Navigate to section:

About this cycle

Nominees for Active and International membership:

  • must be physicians who have “accomplished meritorious original, creative, and independent investigations in the clinical or allied sciences of medicine” and who enjoy “unimpeachable moral standing in the medical profession” (as stated in the ASCI bylaws);
  • may not be nominated more than three times; and
  • must be age 50 or younger on January 1, 2026.

Proposers are discouraged from nominating those whose qualifications may not be sufficiently advanced, or from re-nominating a candidate if the candidate’s work has changed little since their previous nominations.

The ASCI Council reviews nominations and may recommend up to 100 Active and International nominees for election. The Council presents the recommended nominee group to Active and Senior members to approve by vote. Those elected for 2026 will be recognized at the ASCI’s annual Dinner and New Member Induction Ceremony, April 17, 2026, as part of the 2026 AAP/ASCI/APSA Joint Meeting, April 17-19, at the Swissôtel Chicago.

Note that Council members may not serve in any capacity regarding nominations.

Nomination preparation guidance and instructions

A nomination requires one Proposer and one Seconder, both of whom must be ASCI members in good standing and (if applicable) current in Society dues. General Supporters are optional and are not required to be ASCI members. Note that Emeritus members may participate in any of these roles.

Note: A nominee may request that the nomination be set up for her/his editing by sending an email to staff@the-asci.org; if a Proposer has been identified, provide that person’s name in the request. 

There is no limit to the number of nominations a member can propose or support (either as Seconder or General Supporter).

The Proposer is ideally from an institution different from the nominee’s institution (although this is not required) and should have a good understanding of the nominee’s work. The Proposer is responsible for:

  • starting the nomination (see “ASCI account access” below);
  • granting access to the nominee to edit certain sections of the nomination (see detail in “Nomination sections” below); note that granting access is required, as demographic information can be supplied only by the nominee;
  • providing the “Proposer’s general statement on the nominee” (500-word limit) and “Statement on progress and development since previous nomination” (if applicable, 500-word limit);
  • ensuring that the nomination is accurate and complete; and
  • submitting the nomination.

Nominees can, when granted access, edit sections of the nomination except those exclusive to the Proposer. Only the nominee can provide demographic information, including research domain(s).

The Seconder is ideally from an institution different from the nominee’s institution (although this is not required) and should have a good understanding of the nominee’s work. The Seconder is responsible for completing and submitting a form that includes:

  • scores for the areas enumerated in the form;
  • comments (500-word limit) that supplement, but do not duplicate, information provided by the Proposer and deal specifically with the nominee’s original scientific contributions; and
  • a description of the relationship to the nominee.

General Supporters (not required; limited to 3 per nomination) may help to provide additional context for a nominee’s contributions, and to demonstrate wider support for the nominee beyond the candidate’s own institution, particularly if the Proposer and Seconder of a nomination are from the nominee’s institution. Anyone (including any ASCI member except those on the ASCI Council) may serve as a General Supporter. The General Supporter completes and submits a form that includes:

  • scores for the areas enumerated in the form;
  • comments (250-word limit) that supplement, but do not duplicate, information provided by the Proposer or the Seconder and deal specifically with the nominee’s original scientific contributions; and
  • description of the relationship to the nominee.

A nomination support template may be referenced in order to aid in drafting comments. Please note, however:

  • General Supporters who are ASCI members should complete and submit the required information online through their member accounts (see “ASCI account access”).
  • General Supporters who are not ASCI members should request that the Proposer add them to the nomination. The Proposer is then able to send an email containing information about accessing the support form on the ASCI website.

ASCI account access

  • Access your account
  • Go to the “Activities / nominations” tab, navigate to the “Active and International membership” section, and click on Search for a nominee.
  • Enter the nominee’s last name (you may enter a partial name):
    • If the nominee is found, you’ll be prompted to select your role if available: Proposer, Seconder, or General Supporter.
    • If the nominee isn’t found, provide the requested information to add the nominee and start the nomination by selecting your role (see bullet point immediately preceding).

Nomination sections

  • About the nominee
    — Proposer and nominee may edit this information.
  • Nominee’s demographic information
    — Only the nominee may edit this information.
    The ASCI requests responses to questions in a brief, 9-section survey that will help provide the foundation for expanding diversity, fostering inclusion, and achieving equity in the ASCI. All response areas are voluntary, with a “Prefer not to answer” option available for each section. Anyone with access to person-specific information (such as ASCI leadership, members associated with review processes, and staff members) will be required to keep the information confidential. Depersonalized summary information of all response areas may be provided in periodic public reports.
  • Nominee’s research domain(s)
    — Only the nominee may edit this information.
  • Nominee’s institutional affiliation
    — Proposer and nominee may edit this information.
  • Support for nomination
    — Only the Proposer has access to this section.
    Proposers may attach the Seconder and General Supporters to the nomination by searching the ASCI member directory. For a supporter who is not an ASCI member, Proposers must supply the supporter’s name and email address in order to attach the person to the nomination. After supporters are attached to the nomination, Proposers are provided the ability to notify them regarding their support forms.
  • Nominee’s biography
    — Proposer and nominee may edit this information.
    Limited to 300 words, this brief summary of the nominee’s research and accomplishments will not be evaluated for review, but will be used to populate the nominee’s ASCI directory entry if the nominee is elected.
  • Documents
    — Proposer and nominee may edit this information:

    • Full academic curriculum vitae, including:
      • current funding (clearly indicate whether the nominee is a principal investigator),
      • past funding,
      • invited lectures,
      • patents, and
      • full bibliography (with original research separated from other types of publications and the nominee’s name presented in bold face).
    • NIH-style biographical sketch (5-page limit), following the current format available at:
      http://grants.nih.gov/grants/forms/biosketch.htm
    • A high-resolution headshot photograph (for use if the nominee is recommended for election)
    • Three “Most significant publications,” excluding those representing work done by the nominee as a trainee. For each of these three files, an annotation is required and consists of three aspects:
      1. Citation: Author list in the original publication sequence, with the nominee’s name in capital letters, followed by numbered notation of the nominee’s role in parentheses (1 = principal investigator, 2 = collaborator), title, journal name, volume, inclusive page numbers, and year: Example:
        “John Q. Public and JANE DOE (1). Title. Journal. 1:1-10 (2015).”
      2. Pubmed ID (PMID).
      3. Annotation: A description (50-word limit) of the publication’s key findings and significance.
  • Seminal contribution(s)
    —  Proposer and nominee may edit this information.
    Summarize the nominee’s defining seminal contribution(s) and why this work forms the basis for the nomination (75-word limit). Use of lay terminology is encouraged.
  • Proposer’s general statement on the nominee
    — Only the Proposer has access to this section.
    In the Proposer’s own words (500-word limit), describe the quality, originality, and impact of the nominee’s scientific work and the consistency and importance of the nominee’s research theme. Include a statement on the level of independence from the nominee’s mentor(s) and the nominee’s productivity and stature in the field.

    • Proposers should expand upon the candidate’s seminal contribution(s), including the originality, novelty, and impact of this research on the field. Note any special circumstances (e.g., childbearing or personal/family illness) that influenced the candidate’s research activities.
    • Information regarding major awards, invitations to give plenary lectures (especially at national and international meetings), and invitations to write chapters in major textbooks should be included as applicable — the quality and quantity of work are important factors.
  • Statement on progress and development since previous nomination
    — Proposer and nominee may edit this information.
    In the Proposer’s own words (500-word limit), describe the critical differences between this nomination and the previous nomination (if applicable).

Recipient of the 2025 Louis W. Sullivan, MD, Award: Consuelo H. Wilkins, MD, MSCI

Consuelo H. Wilkins, MD, MSCI
Dr. Wilkins

The American Society for Clinical Investigation is pleased to recognize Consuelo H. Wilkins, MD, MSCI, as recipient of the 2025 ASCI/Louis W. Sullivan, MD, Award, for her groundbreaking contributions in community engagement and health equity, including large-cohort imaging studies suggesting that amyloid-directed therapies are less likely to benefit Black, Hispanic, and Asian individuals with memory loss. Dr. Wilkins receives an honorarium of $10,000 and delivers a scientific talk at the 2026 AAP/ASCI/APSA Joint Meeting.

As part of her work in Alzheimer’s disease, Dr. Wilkins used amyloid PET imaging on large cohorts of individuals with memory loss and found that the odds of having a positive scan were lower among Black, Latino, and Asian populations. The results indicate that fewer people in these groups will be eligible for recently approved anti-amyloid therapies compared with White individuals.

Dr. Wilkins’ research has transformed efforts to increase clinical research engagement and improve health outcomes for all. Her team established the Community Engagement Studio (CES), a formalized approach to incorporating the voice of community stakeholders at all stages of clinical research — a model adopted by numerous studies and many academic health centers in the US, Canada, and the United Kingdom. Dr. Wilkins has developed and validated instruments to measure trust in research and standards for compensating community partners. She has created frameworks that serve as a blueprint for academic medical centers to personalize care based on the needs of their populations.

Dr. Sullivan’s transformational work has been an inspiration for me. My work spans clinical research, policy-focused systems change, and advocacy for health equity – all of which are areas where Dr. Sullivan is an icon. In my current roles, I have the unique opportunity to leverage my research to build new programs and develop institutional policies that ensure everyone has an opportunity to achieve optimal health.

– Dr. Wilkins

Dr. Jeffrey R. Balser, President and CEO, Vanderbilt University Medical Center (VUMC) and Dean, Vanderbilt University School of Medicine, nominated Dr. Wilkins for this recognition. He wrote, “Dr. Wilkins embodies the spirit of the Award through her groundbreaking work. Her research, particularly in Alzheimer’s disease, has reshaped the field. She leads initiatives that measurably enhance participation from all communities and promote institutional change.”

Dr. Wilkins received her MD from Howard University College of Medicine, completed a residency at Duke University Medical Center and fellowship in geriatric medicine at Barnes-Jewish Hospital/Washington University School of Medicine; and received her MSCI from Washington University School of Medicine. She is currently Senior Vice President and Senior Associate Dean for Community Health and Engagement, Mildred Thornton Stahlman Chair in Rural Health, and Professor of Medicine, VUMC; and Associate Director, Vanderbilt Institute for Clinical and Translational Research. She was elected to the National Academy of Medicine in 2020 and to the ASCI in 2022.

The 2025 Harrington Prize for Innovation in Medicine: Owen N. Witte, MD

The twelfth annual Harrington Prize for Innovation in Medicine has been awarded to Owen N. Witte, MD, Distinguished University Professor and President’s Chair in Developmental Immunology, David Geffen School of Medicine, University of California, Los Angeles. The award recognizes his foundational discoveries of targeted therapies that have transformed modern cancer treatment.

The Harrington Prize for Innovation in Medicine, established in 2014 by the Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation (ASCI), honors physician-scientists who have moved science forward with achievements notable for innovation, creativity and potential for clinical application.

Dr. Witte is internationally known for his contributions to the understanding of human leukemias and immune disorders. His work revealed the critical role of enzymes called tyrosine kinases in human disease.

Dr. Witte discovered one of the first tyrosine kinases, the ABL oncoprotein, showing that its activity is responsible for causing chronic myeloid leukemia (CML)—a cancer of white blood cells. He predicted that drugs that inhibit the tyrosine kinase would have therapeutic benefit. Based on Dr. Witte’s work, the drug imatinib, an inhibitor of tyrosine kinase ABL, was developed as frontline therapy. Imatinib increases the 8-year survival rate for CML from 6% to 87%.

Dr. Witte subsequently discovered Bruton’s tyrosine kinase (BTK). He provided evidence that BTK’s tyrosine kinase activity was important for both normal immune function (loss of BTK led to immunodeficiency disease) and white blood cell cancers—ultimately spurring the development of the BTK inhibitor drug ibrutinib, now used to treat several types of lymphomas and leukemias.

“It is a great honor to present Dr. Witte with the Harrington Prize for Innovation in Medicine. His transformative contributions to cancer research have not only reshaped our understanding of leukemia, lymphoma, and epithelial cancers but have also revolutionized targeted therapies, directly impacting countless lives. His seminal contributions to the development of ABL and BTK inhibitors exemplifies the scientific creativity and impact this award stands for,” said Anna Greka, MD, PhD, Professor of Medicine at Harvard Medical School, Physician at Mass General Brigham, Core Institute Member of the Broad Institute of MIT and Harvard, and 2024-2025 ASCI President.

“Dr. Witte’s remarkable work serves as a powerful illustration of how basic discovery can inform the development of life-saving therapies. His groundbreaking work has bridged the gap between the laboratory bench and the clinical bedside, extending human life,” said Jonathan S. Stamler, President & Co-Founder, Harrington Discovery Institute, Robert S. and Sylvia K. Reitman Family Foundation Chair of Cardiovascular Innovation, Distinguished University Professor, and Professor of Medicine and of Biochemistry at University Hospitals and Case Western Reserve University.

A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers from six countries before selecting the 2025 Harrington Prize recipient.

In addition to receiving the Prize’s $20,000 honorarium, Dr. Witte will deliver the Harrington Prize Lecture at the 2025 AAP/ASCI/APSA Joint Meeting on April 25-27, and he will be a featured speaker at the 2025 Harrington Scientific Symposium May 21-22 and is invited to publish an essay in the Journal of Clinical Investigation.

Joint ASCI/AAP Statement on American Health and the Biomedical Research Enterprise

At this time of uncertainty across the U.S. biomedical and public health enterprise, the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP) stand with our members and physician-scientists of all career stages, including early stage investigators who are building their careers. We continue to track current events and we are working with colleagues across all States and partner organizations to understand the challenges we face – and to propose solutions.

All of us share in the joy of scientific discovery, the excitement of mentoring the newest generation of physician-scientists, and advancing our shared mission to improve the health of all Americans. As such, our work aligns well with our nation’s founding principle: “e pluribus unum.” Out of many, one.

In this spirit, we call on everyone to work with urgency toward securing and sustaining our workforce, with special consideration for the emerging generations of physician-scientists. This is the only way we can continue to fuel our country’s unparalleled innovation engine, our economic prosperity, and our health in the decades ahead. It is up to us, all of us.

With respect and gratitude,

— The Councils of the ASCI and the AAP

Call for submissions: ASCI member host labs, 2025–2027

As part of the ASCI’s Postbac Program, the ASCI is pleased to call for submissions from Society members who are interested in their labs serving as hosts for Program finalists for 2025–2027.

Any member can provide a submission by:

The deadline for submissions is March 3, 2025, 11:59 pm Eastern.

Submissions consist of the following sections:

  • Your information
    • Your institution
    • Your trainee table (PDF upload)
  • About your lab
    • Lab website
    • Lab description and environment (500-word limit). Provide detail on mentoring awards, motivation for applying, and mentorship plan (what presentation will be expected, feedback provided, and participation).
    • Lab member who would be assigned for day-to-day mentoring of the postbac (name, position)
    • Assignee’s biosketch (PDF upload)
  • Institutional resources
    • Provide detail on aspects such as the requisite amount of bench/desk space in lab, faculty member to work with the student on medical-school essay, institutional career development, and educational and networking opportunities.
    • Institutional stipend levels. The ASCI expects stipends to fall within the ranges of the NIH post-bac IRTA program, with the understanding that the cost of living ranges widely depending on location. Provide information for 2025–2026 and 2026–2027.
    • Indicate if you are able to supplement beyond your institution’s stipend amounts or beyond the ASCI’s maximum grant of $55,000 ($50,000 direct; $5,000 indirect).

Nominations for ASCI Council, 2025

  • Access your member account
  • Go to the “Nominations” tab
  • In the section for “Council vacancies”:
    • If you are the nominee, select the “I’m the nominee” option to start your part of the nomination (only you have access to this information).
    • If you are the nominator, select “I’m the nominator” option, then search for your nominee. Only nominees who are within the age-eligibility criteria will be returned in the results.

    The Society seeks nominations for the following ASCI Council vacancies arising in 2025 (all terms begin and end in the spring):

    • Vice President (4-year term, 2025-2029)
    • Councilor (2 positions, 3-year term, 2025-2028)

    Those eligible for nomination must be in the Active category and:

    • for Vice President, do not turn 56 until 2030 or later
    • for Councilor, do not turn 56 until 2029 or later

    The Society strongly encourages members to consider diversity in identifying those suitable for nomination. Self-nominations are not permitted. Nominations may be submitted by any member in good standing (with dues up to date if applicable) and must be submitted by February 17, 2025, at 11:59 PM EST.

    All Council members are expected to support the activities of and attend the ASCI annual meeting, and to participate in the general governance of the Society, including two in-person meetings (fall and spring, with the spring meeting occurring as part of the annual meeting) and videoconference calls (typically every other month). All Council members participate in the review of membership and various award nominations and subsequent discussion at the fall meeting.

    The Vice President transitions to President-Elect in year 2, President in year 3, and Immediate Past President in year 4. For the 2nd through 4th years of this position, this member is expected to participate significantly in matters related to the annual meeting. In the Presidential year (year 3), the member convenes a face-to-face Council meeting and oversees related review processes for nominations, notably including those to membership. The President works closely with the Association of American Physicians to create the annual meeting program and presents the traditional Presidential Address at the meeting.

    The Council is supported by an Executive Director, Managing Director, and other staff members who oversee the day-to-day operations of the Society and effect initiatives as directed by the Council. For details on Officers and Councilors, see the ASCI Bylaws.

    Nominators:

    • may be any ASCI member
    • must provide a statement (250-word limit) regarding the nominee

    Nominees:

    • must specify the position of interest (Vice President, Councilor);
    • provide a 250-word candidate statement, written in first person, for consideration by the Council and for use as the ballot statement if the nominee is selected as a candidate (nominees may refer to candidate statements for the 2024 nomination cycle for guidance in drafting their own statements);
    • provide an NIH-style biosketch;
    • must complete the ASCI’s demographic survey and provide information about research domain(s).

    To start a nomination:

    • Access your member account
    • Go to the “Nominations” tab
    • In the section for “Council vacancies”:
      • If you are the nominee, select the “I’m the nominee” option to start your part of the nomination (only you have access to this information).
      • If you are the nominator, select “I’m the nominator” option, then search for your nominee. Only nominees who are within the age-eligibility criteria will be returned in the results.

      The ASCI’s 2025 Active and International elected members

      The ASCI is pleased to announce the election of 99 Active and International members for 2025.

      These new members come from 46 different institutions and represent excellence across the breadth of academic medicine. They will be officially inducted into the Society at the ASCI Dinner and New Member Induction Ceremony, April 25, 2025, as part of the AAP/ASCI/APSA Joint Meeting, April 25–27, at the Swissotel Chicago.

      Active and International members, 2025

      Daniel Addison, MD
      Ohio State University College of Medicine
      Sally Nneoma Sarah Adebamowo, MBBS, MSc, ScD
      University of Maryland School of Medicine
      Manmeet Singh Ahluwalia, MD, MBA
      Florida International University
      Niroshana Anandasabapathy, MD, PhD
      Weill Cornell Medicine
      Jason Randolph Andrews, MD
      Stanford University School of Medicine
      Saro H. Armenian, DO, MPH
      City of Hope Medical Center
      Pratiti Bandopadhayay, MBBS, PhD
      Harvard Medical School, Dana-Farber Cancer Institute
      Alexander G. Bick, MD, PhD
      Vanderbilt University Medical Center
      Ranjit S. Bindra, MD, PhD
      Yale School of Medicine
      Eli A. Boritz, MD, PhD
      NIH, National Institute of Allergy and Infectious Diseases (NIAID)
      David A. Braun, MD, PhD
      Yale School of Medicine
      Joshua D. Brody, MD
      Icahn School of Medicine at Mount Sinai
      Cesar Martin Castro, MD, MS, MMSc
      Harvard Medical School, Massachusetts General Hospital
      Andrea Cercek, MD
      Memorial Sloan Kettering Cancer Center
      Rohit Chandwani, MD, PhD
      Weill Cornell Medicine
      Daniel I-Hsin Chu, MD, MSPH, FACS, FASCRS
      University of Alabama at Birmingham School of Medicine
      Nicole G. Coufal, MD, PhD
      University of California, San Diego, School of Medicine
      Mucio Kit Delgado, MD, MS
      University of Pennsylvania Perelman School of Medicine
      Rajat Deo, MD, MTR
      University of Pennsylvania Perelman School of Medicine
      Jörg Hans Wilhelm Distler, MD
      Heinrich-Heine-University Duesseldorf
      Michael Thomas Eadon, MD
      Indiana University School of Medicine
      Yi Fan, MD, PhD
      University of Pennsylvania Perelman School of Medicine
      Mariella G. Filbin, MD, PhD
      Harvard Medical School, Dana-Farber Cancer Institute
      Terence Peter Gade, MD, PhD
      University of Pennsylvania Perelman School of Medicine
      Ethan M. Goldberg, MD, PhD
      Children’s Hospital of Philadelphia
      Misty Good, MD, MS
      University of North Carolina School of Medicine
      Madhusudan Grover, MBBS
      Mayo Clinic
      Rajat M. Gupta, MD
      Harvard Medical School, Brigham & Women’s Hospital
      Lida P. Hariri, MD, PhD
      Harvard Medical School, Massachusetts General Hospital
      Takashi Hato, MD
      Indiana University School of Medicine
      Jorge Henao-Mejia, MD, PhD
      University of Pennsylvania Perelman School of Medicine
      Angela Christine Hirbe, MD, PhD
      Washington University School of Medicine in St. Louis
      Lori Rachel Holtz, MD, MSPH
      Washington University School of Medicine in St. Louis
      William Tzu-lung Hu, MD, PhD, FAAN
      Rutgers, Robert Wood Johnson Medical School
      Alison Ju-Tsu Huang, MD, MAS
      University of California, San Francisco, School of Medicine
      Jason T. Huse, MD, PhD
      University of Texas MD Anderson Cancer Center
      Tamara Isakova, MD, MMSc
      Northwestern University Feinberg School of Medicine
      Prasanna Jagannathan, MD
      Stanford University School of Medicine
      Tobias Janowitz, MBBChir, PhD
      Cold Spring Harbor Laboratory
      Robert R. Jenq, MD
      City of Hope Medical Center
      Wen Jiang, MD, PhD
      University of Texas MD Anderson Cancer Center
      Sadiya Sana Khan, MD, MSc
      Northwestern University Feinberg School of Medicine
      John B. Kisiel, MD, MS
      Mayo Clinic
      Jeffery M. Klco, MD, PhD
      St. Jude Children’s Research Hospital
      Liza (Yelizaveta) Konnikova, MD, PhD
      Yale School of Medicine
      Jonathan Andrew Kropski, MD
      Vanderbilt University School of Medicine
      Hrishikesh S. Kulkarni, MD, MSCI
      University of California, Los Angeles, David Geffen School of Medicine
      Sonia S. Kupfer, MD
      University of Chicago Pritzker School of Medicine
      Angelle Desiree LaBeaud, MD, MS
      Stanford University School of Medicine
      Anne C.C. Lee, MD, MPH
      Brown University Medical School
      Katherine Phoenix Liao, MD, MPH
      Harvard Medical School, Brigham & Women’s Hospital
      Robbie G. Majzner, MD
      Harvard Medical School, Dana-Farber Cancer Institute
      Rajeev Malhotra, MD, MA
      Harvard Medical School, Massachusetts General Hospital
      Joseph D. Mancias, MD, PhD
      Harvard Medical School, Dana-Farber Cancer Institute
      Nilam S. Mangalmurti, MD
      University of Pennsylvania Perelman School of Medicine
      Folasade P. May, MD, PhD, MPhil
      University of California, Los Angeles, David Geffen School of Medicine
      Megan E. McNerney, MD, PhD
      University of Chicago Pritzker School of Medicine
      Jaimie P. Meyer, MD, MS, FACP
      Yale School of Medicine
      Derek P. Narendra, MD, PhD
      National Institutes of Health
      Brian Timothy O’Neill, MD, PhD
      University of Iowa Carver College of Medicine
      Stephen T. Oh, MD, PhD
      Washington University School of Medicine in St. Louis
      Opeyemi A. Olabisi, MD, PhD
      Duke University School of Medicine
      Matthew G. Oser, MD, PHD
      Harvard Medical School, Dana-Farber Cancer Institute
      Eric Padron, MD
      Moffitt Cancer Center
      Akash Patnaik, MD, PhD, MMSc
      University of Chicago Pritzker School of Medicine
      Tien Peng, MD
      University of California, San Francisco, School of Medicine
      Paige M. Porrett, MD, PhD
      University of Alabama at Birmingham School of Medicine
      Camille E. Powe, MD
      Harvard Medical School, Massachusetts General Hospital
      David R. Raleigh, MD, PhD
      University of California, San Francisco, School of Medicine
      Deepak A. Rao, MD, PhD
      Harvard Medical School, Brigham & Women’s Hospital
      Meenakshi Rao, MD, PhD
      Harvard Medical School, Boston Children’s Hospital
      Abby Rachel Rosenberg, MD, MS, MA
      Harvard Medical School, Dana-Farber Cancer Institute
      Kathryn J. Ruddy, MD
      Mayo Clinic
      Elias Joseph Sayour, MD, PhD
      University of Florida College of Medicine
      Philip Oliver Scumpia, MD, PhD
      University of California, Los Angeles, David Geffen School of Medicine
      Chetan Seshadri, MD
      University of Washington School of Medicine
      Nilay Sethi, MD, PhD
      Harvard Medical School, Dana-Farber Cancer Institute
      Nirali N. Shah, MD, MHSc
      NIH, National Cancer Institute (NCI)
      Keith Magnus Sigel, MD, PhD, MPH
      Icahn School of Medicine at Mount Sinai
      Emily K. Sims, MD
      Indiana University School of Medicine
      Zirui Song, MD, PhD
      Harvard Medical School, Massachusetts General Hospital
      Tomokazu Souma, MD, PhD
      Duke University School of Medicine
      Kathryn Elaine Stephenson, MD, MPH
      Harvard Medical School, Beth Israel Deaconess Medical Center
      Sean Robinson Stowell, MD, PhD
      Harvard Medical School, Brigham & Women’s Hospital
      Paul C. Tang, MD, PhD
      Mayo Clinic
      Justin Taylor, MD
      University of Miami Miller School of Medicine
      Marmar Vaseghi, MS, MD, PhD
      University of California, Los Angeles, David Geffen School of Medicine
      Elizabeth C. Verna, MD, MSc, FAASLD, FAST
      Columbia University Vagelos College of Physicians and Surgeons
      Srinivas Raghavan Viswanathan, MD, PhD
      Harvard Medical School, Dana-Farber Cancer Institute
      Daniel R. Wahl, MD, PhD
      University of Michigan Medical School
      Amisha Wallia, MD, MS
      Northwestern University Feinberg School of Medicine
      Taia T. Wang, MD, PhD
      Stanford University School of Medicine
      Marc Nathan Wein, MD, PhD
      Harvard Medical School, Massachusetts General Hospital
      Craig Brian Wilen, MD, PhD
      Yale School of Medicine
      Michael Robert Wilson, MD, MAS
      University of California, San Francisco, School of Medicine
      Graeme F. Woodworth, MD
      University of Maryland School of Medicine
      Kelley Yan, MD, PhD
      Columbia University Vagelos College of Physicians and Surgeons
      Dmitriy Zamarin, MD, PhD
      Icahn School of Medicine at Mount Sinai
      Lilei Zhang, MD, PhD
      Baylor College of Medicine

      Please join us in congratulating these newly elected members!

      Nominations open for 2025 Honorary membership

      The ASCI is pleased to call for nominations for 2025 Honorary membership. Nominees for this recognition must fit the criteria as given in the ASCI bylaws:

      Any distinguished person who has contributed significantly to the Society’s objectives, who has not been previously and unsuccessfully nominated for Active or International membership, and who enjoys an unimpeachable moral standing is eligible for nomination in this category.

      For the nominee who meets these criteria, there is no restriction on age or degree held.

      The deadline for receipt of nominations is February 17, 2025, at 11:59 pm Eastern. Nominations will be screened to ensure they are complete and fit the nomination criteria. The Council reviews nominations and submits its recommendations to Active and Senior members for approval.

      The nominator must be an ASCI member in good standing and must start the nomination:

      • Access your member account
      • Go to the “Nominations” tab, then to the “Honorary membership nomination” section
      • Select “I’m the nominator” option
      • Search for your nominee:
        • If found, click on “Start nomination”
        • If no result is found, provide and save the requested information (first name, last name, and email address), then click on “Start nomination” for the newly created nominee in the “Results” section
      • At the top of the nomination form, click on “Send access notification to the nominee at: <email>”
      • Provide a 250-word limit statement on the nominee’s qualifications
      • Submit the statement, which can be done regardless of whether the nominee’s part of the nomination is completed

      The nominee receives an email with information to access their part of the nomination and then must:

      • Provide a birth date and address information
      • Provide a brief (300-word limit) biography
      • Provide current institutional affiliation
      • Upload a full curriculum vitae
      • Complete a demographics survey
      • Identify research domain(s)
      • Submit this aspect of the nomination, which can be done regardless of whether the nominator or supporter has completed their statement